)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Neuronetics
Neuronetics (STIM) investor relations material
Neuronetics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
Q3 revenue was $41.962M, up 12.5% YoY; gross margin reached 52.2%, and operating income and Adjusted EBITDA turned positive at $0.541M and $1.887M.
Results improved, but a projected March 2027 revenue-covenant shortfall creates substantial going-concern uncertainty.
Financial highlights
Q3 gross profit was $21.890M versus $17.108M; gross margin was 52.2% versus 45.9% YoY.
Operating expenses fell to $21.349M from $24.429M; operating income was $0.541M versus a $7.321M loss.
Net loss attributable to stockholders was $1.692M, or $0.02 per share, versus $9.045M, or $0.13 per share; Adjusted EBITDA was $1.887M versus a $4.670M loss.
Nine-month revenue rose 10% to $118.0M; net loss narrowed to $15.8M from $31.9M, and operating cash use fell to $9.2M from $21.3M.
Outlook and guidance
FY 2026 revenue guidance remains $160M–$164M; gross margin guidance is 49%–50%, raised from 48%–50%.
FY 2026 operating expense guidance is $92.5M–$95.5M, or $89M–$92M excluding estimated $3.5M stock-based compensation.
FY 2026 cash flow from operating and investing activities is forecast at negative $10M to negative $12M, improved from prior guidance of negative $10.5M to negative $14.5M.
Revenue-covenant compliance and lender discussions remain pivotal; revenue-cycle improvements, clinic treatment options, and NeuroStar sales and product-mix strategies do not fully mitigate the risk.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Neuronetics
- Q2 2026 revenue up 9.1% to $41.6M, gross margin 51.1%, net loss narrowed, liquidity risks persist.STIM
Q2 2026 - Director elections, auditor ratification, and equity plan all approved without shareholder questions.STIMAGM 2026
- Q1 revenue up 8% to $34.5M, net loss narrows, but going concern risk remains.STIMQ1 2026
- Votes sought for director elections, auditor ratification, compensation, and equity plan.STIMProxy filing
- Annual meeting to vote on directors, auditor, executive pay, and new equity plan, with strong governance focus.STIMProxy filing
- Over 20 million shares registered for resale post-acquisition, with no proceeds to the company.STIMRegistration Filing
- Q4 revenue up 86% YoY, 23% pro forma, with positive cash flow and 2026 growth outlook.STIMQ4 2025
- Q3 revenue up 4% to $18.5M; Greenbrook deal approved, boosting growth and synergies.STIMQ3 2024
- Acquisition and integration of Greenbrook TMS set the stage for growth and operational synergies.STIMCanaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024
Next Neuronetics earnings date
Q4 20262 Mar, 2027
Neuronetics
Next Neuronetics earnings date
Q4 20262 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Neuronetics Inc develops and markets non-invasive neurostimulation therapies for mental health disorders. The company’s primary product is a transcranial magnetic stimulation system used in the treatment of major depressive disorder and other psychiatric conditions. It serves healthcare providers in the United States. The company is headquartered in Malvern, Pennsylvania, and its shares are listed on the NASDAQ.